BIOTON insulin has been providing effective treatment to diabetes patients all over the world for 20 years now. We are pleased to announce that we have received  registration approval in more countries. 

Insulin is being supplied  to markets in Europe, Latin America, Asia and Africa. In 2019 and 2020, Malta, Yemen and Nigeria joined the new countries where our company’s insulin is available. Since then, we have expanded our export operations to Egypt, Hong Kong and Tunisia. 

We are resting on your laurels. We are registering our insulin  in Morocco, Kenya, Brazil, Brunei and the Dominican Republic. 

Jeremy Launders, CEO of BIOTON S.A., said:  

“Our products are registered in almost 30 countries on four continents. In Europe we are in Poland, but also in Malta, Bosnia and Herzegovina, Ukraine or Belarus. We are also in Asia, Africa and Latin America. In addition, we also work with global public health organisations. When such an organisation reports that there is a shortage of insulin in a country, we are ready to help to supply it. 

We want to focus on growth in our current markets and strengthen our presence in Latin America. We are in the registration process in Brazil, we are starting the registration process in Mexico. These are countries with large populations, so the demand for insulin there is significant.” 

Responding to the diverse needs of partners, we supply finished forms of insulins or the active ingredient. We are continuously working to increase the availability of our insulins in more countries.